CHRS
Coherus Oncology, Inc.
CHRS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink.
CHRS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
CHRS's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
CHRS PE Valuation
CHRS has no meaningful PE right now: it lost money over the past year.
CHRS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect CHRS's losses to shrink, with revenue growing.
CHRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.00 | -172% |
| Q2 2026 | -$1.06 | -166% |
| Q1 2026 | $1.64 | +$2.71 |
| Q4 2025 | $1.43 | +472% |
| Q3 2025 | $1.39 | +$1.43 |
| Q2 2025 | $1.61 | +$1.97 |
| Q1 2025 | -$1.07 | -$0.33 |
| Q4 2024 | $0.25 | +$2.78 |
CHRS has swung to a loss: it lost $1.00 per share over the past year, after a profit the year before.
CHRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $14.3M | +23% |
| Q2 2026 | $14.3M | +40% |
| Q1 2026 | $12.3M | +62% |
| Q4 2025 | $12.7M | -76% |
| Q3 2025 | $11.6M | -84% |
| Q2 2025 | $10.3M | -84% |
| Q1 2025 | $7.6M | -90% |
| Q4 2024 | $54.1M | -41% |
CHRS's revenue is recovering but still below its 2020 peak: $14M last quarter, up 23% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -236% | +147 points |
| Q2 2026 | -226% | +218 points |
| Q1 2026 | -294% | +304 points |
| Q4 2025 | -360% | -282 points |
| Q3 2025 | -383% | -374 points |
| Q2 2025 | -444% | -412 points |
| Q1 2025 | -598% | -543 points |
| Q4 2024 | -78% | -2.7 points |
CHRS's operating margin was −236% last quarter, up 147 points from the same quarter a year ago.
CHRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34M | +$12.3M |
| Q2 2026 | -$62.1M | -$15.5M |
| Q1 2026 | -$57.9M | -$32.1M |
| Q4 2025 | -$19.7M | -169% |
| Q3 2025 | -$46.3M | +$15.7M |
| Q2 2025 | -$46.6M | -178% |
| Q1 2025 | -$25.8M | +$20.9M |
| Q4 2024 | $28.6M | +$41.6M |
CHRS has burned cash in most quarters: −$174M over the past year, against −$90M the year before.
CHRS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +154K shares |
| 1 year | +34% | +38.9M shares |
| 3 years | +78% | +67.7M shares |
| 5 years | +105% | +79.4M shares |
| Available history | +112% | +81.8M shares |
CHRS has 155M diluted shares, up 34% from a year ago.
CHRS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2020 | -2.9x | Net Cash |
| Q3 2020 | -1.1x | Net Cash |
| Q2 2020 | -0.7x | Net Cash |
| Q1 2020 | -0.7x | Net Cash |
| Q4 2019 | -0.9x | Net Cash |
CHRS has more cash than debt.
CHRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.9 | Oversold |
| Stochastic | 3.7 | Oversold |
CHRS's weekly RSI is 24 (oversold) and its Stochastic is 4 (oversold).
CHRS PE vs Healthcare Sector
| Metric | CHRS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CHRS has no meaningful PE right now: it lost money over the past year.
CHRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.94 | 43% below |
| 20 week MA | $1.21 | 55% below |
| 50 week MA | $1.46 | 63% below |
| 100 week MA | $1.30 | 58% below |
| 200 week MA | $2.34 | 77% below |
CHRS is in a downtrend: it's below all five of its weekly moving averages, and 77% below its 200-week average.
CHRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18.2 | $17.4 | -4.7% |
| 2021 | $17.4 | $17.8 | +2.5% |
| 2022 | $17.8 | $6.45 | -64% |
| 2023 | $6.45 | $3.33 | -48% |
| 2024 | $3.33 | $1.49 | -55% |
| 2025 | $1.49 | $1.33 | -11% |
| 2026 YTD | $1.33 | $0.54 | -59% |
CHRS has finished four years in a row lower, and it's down 59% so far in 2026.